A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
- Generic Use Rate at 54.7% in July-September 2015: JGA
January 6, 2016
- Fuji Pharma Licenses Nesp Biosimilar from S. Korean Firm
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Torii Files NDA for Allergen Immunotherapy Tablet for Cedar Pollinosis
January 5, 2016
- ASKA Files Rifaximin for Hepatic Encephalopathy
December 25, 2015
- Bristol-Myers Files Elotuzumab for Relapsed, Refractory Multiple Myeloma in Japan
December 25, 2015
- FDA OKs Selexipag Originated by Nippon Shinyaku
December 24, 2015
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- Israel’s Pluristem Therapeutics to Enter into Japanese Regenerative Medicine Market
December 24, 2015
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
ページ
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…